In vitro activity of BAY v 3522, a new oral cephalosporin.

AUTOR(ES)

Fass, R J

RESUMO

The in vitro activity of BAY v 3522 was compared with the activities of cephalexin, cefaclor, cefuroxime, cefixime, and amoxicillin-clavulanate. MICs (in micrograms/ml) of BAY v 3522 were as follows: Staphylococcus spp. (except for oxacillin-resistant strains), 0.13 to 1; Streptococcus spp. (except for some viridans group streptococci), less than or equal to 0.015 to 0.25; Enterococcus faecalis, 2 to 8; other enterococci, 0.5 to greater than 32; beta-lactamase-negative Haemophilus influenzae and Branhamella catarrhalis, 0.13 to 1; beta-lactamase-positive H. influenzae and B. catarrhalis, 0.5 to 4; Pasteurella multocida, 0.06 to 0.25; and members of the family Enterobacteriaceae, 0.5 to greater than 32. Among the cephalosporins, BAY v 3522 was the most active against gram-positive cocci and cefixime was the most active against gram-negative bacilli; BAY v 3522 was similar in activity to amoxicillin-clavulanate against most species.

Documentos Relacionados

• In vitro activity of BAY v 3522, a new cephalosporin for oral administration.
• In Vitro Activity of BAY v 3522, a New Cephalosporin for Oral Administration
• In vitro activity of Bay v 3522, a new cephalosporin, compared with activities of other agents.
• Mechanism of action of BAY v 3522, a new cephalosporin with unusually good activity against enterococci.
• In vitro activity of BMY-28100, a new oral cephalosporin.